Market Overview - The Shanghai Composite Index closed at 3844.84 points, above the six-month moving average, with a decline of 0.79% [1] - The total trading volume of A-shares reached 19,304.44 billion yuan [1] Stocks Performance - A total of 35 A-shares have surpassed the six-month moving average, with notable stocks including: - Gongsiao Daji (供销大集) with a deviation rate of 6.45% - Jidian Co. (吉电股份) with a deviation rate of 6.05% - *ST Sansheng (ST三圣) with a deviation rate of 4.29% [1] - Stocks with smaller deviation rates that just crossed the six-month line include: - Fuling Co. (富岭股份) - Hubei Energy (湖北能源) - Yunnan Tourism (云南旅游) [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates on September 2: - Gongsiao Daji (供销大集): 9.84% increase, 4.84% turnover rate, latest price 2.68 yuan - Jidian Co. (吉电股份): 7.34% increase, 6.58% turnover rate, latest price 5.56 yuan - *ST Sansheng (ST三圣): 5.10% increase, 2.62% turnover rate, latest price 4.74 yuan [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Huayuan Co. (华原股份): 3.93% increase, 2.74% turnover rate, latest price 17.71 yuan - Meiyan Jixiang (梅雁吉祥): 4.59% increase, 7.21% turnover rate, latest price 2.96 yuan - Qingdao Port (青岛港): 2.31% increase, 0.57% turnover rate, latest price 8.87 yuan [1]

强制执行进展暨收到《执行裁定书》公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 重庆三圣实业股份有限公司（以下简称"公司"或"三圣股份"）控股股 东潘先文先生所持公司 280 万股股份（占其所持公司股份比例为 3.87%，占公司 总股本比例为 0.65%）将通过网络拍卖方式进行司法强制执行。本次股份变动不 会导致公司实际控制权发生变化，不会对公司的治理结构和经营情况产生影响。 最终司法处置结果尚存在不确定性。敬请广大投资者理性投资，注意投资风险。 证券代码：002742 证券简称：*ST 三圣 公告编号：2025-50 号 重庆三圣实业股份有限公司 关于控股股东所持部分股份被司法 公司于 2025 年 7 月 11 日在巨潮资讯网上发布《关于控股股东所持部分股份 被司法强制执行的提示性公告》（公告编号：2025-42），根据重庆市北碚区人 民法院作出的（2025）渝 0109 执恢 536 号之二《执行裁定书》，裁定自公告发 布日起 15 个交易日内通过集中竞价方式强制变现公司控股股东潘先文先生其所 持公司 280 万股股份。截至本公告披露日 ...

Core Viewpoint - *ST San Sheng (002742) reported a significant decline in financial performance for the first half of 2025, with total revenue dropping by 33.89% year-on-year and a net profit loss of 1.31 billion yuan, a decrease of 97.02% compared to the previous year [1] Financial Performance Summary - Total revenue for the first half of 2025 was 486 million yuan, down from 736 million yuan in 2024, reflecting a 33.89% decrease [1] - The net profit attributable to shareholders was -1.31 billion yuan, compared to -66.48 million yuan in the same period last year, marking a 97.02% decline [1] - The gross margin decreased to 20.4%, down 13.97% year-on-year, while the net margin fell to -26.98%, a drop of 212.6% [1] - Total expenses (selling, administrative, and financial) reached 203 million yuan, accounting for 41.76% of total revenue, an increase of 56.69% year-on-year [1] - Earnings per share were -0.3 yuan, a decrease of 97.01% from the previous year [1] Cash Flow and Debt Analysis - The company’s cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at only 3.32% and a negative average operating cash flow to current liabilities ratio over the past three years [4] - The interest-bearing debt ratio has reached 41.44%, indicating a high level of financial leverage [4] - Historical data shows that the company has experienced negative operating cash flow for the past three years, raising concerns about its financial sustainability [4] Investment Return Evaluation - The company's historical return on invested capital (ROIC) has been generally low, with a median ROIC of 7.3% since its listing, and a particularly poor ROIC of -37.06% in 2024 [3] - The company has reported losses in four out of nine annual reports since its IPO, suggesting a lack of consistent profitability [3]

Core Viewpoint - *ST San Sheng reported a revenue of 486 million yuan for the first half of 2025, with a net profit attributable to shareholders of -131 million yuan, indicating ongoing financial challenges while restructuring efforts are progressing [1] Financial Performance - The company achieved an operating revenue of 486 million yuan in the first half of 2025 [1] - The net profit attributable to shareholders was -131 million yuan, and the net profit after deducting non-recurring gains and losses was -127 million yuan [1] - The net cash flow from operating activities improved to 7.15 million yuan compared to the same period last year [1] Restructuring Progress - On August 8, 2025, the Chongqing Fifth Intermediate People's Court accepted the company's restructuring application [1] - The court has allowed the company to continue operations during the restructuring process, which is deemed beneficial for creditors, employees, shareholders, and investors [1] - The restructuring work is reported to be progressing in an orderly manner, with the involvement of Beijing Jindu (Shenzhen) Law Firm and Xinyong Zhonghe Accounting Firm (Special General Partnership) Chongqing Branch as managers [1] - Successful implementation of the restructuring plan is expected to improve the company's asset-liability structure and operational status, promoting a return to healthy and sustainable development [1]

重庆三圣实业股份有限公司 2025 年半年度财务报告 重庆三圣实业股份有限公司 2025 年半年度财务报告 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 77,905,088.94 | 88,868,835.48 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 46,002,119.40 | 42,800,214.15 | | 应收账款 | 426,012,074.78 | 548,715,601.12 | | 应收款项融资 | 8,088,215.73 | 23,287,327.85 | | 预付款项 | 192,898,067.91 | 182,984,300.88 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 11,232,619.17 | 12,166,060.75 | | 其中：应收利息 | | | | 应收股利 | ...

| | | | 2025 | | 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 编制单位：重庆三圣实业股份有限公司 | | | | | | | | | | 单位：人民币万元 | | | | | | | | 2025 年 | | | | | | | | 占用方与上市 | 上市公司核 | 2025 年期初 | 2025 年度占用 | 度占用 | 2025 年度偿还 | 2025年期末 | | | | 非经营性资金占用 | 资金占用方名称 | 公司的关联关 | 算的会计科 | 占用资金余 | 累计发生金额 | 资金的 | 累计发生金额 | 占用资金余 | 占用形成原因 | 占用性质 | | | | 系 | 目 | 额 | （不含利息） | 利息 | | 额 | | | | | | | | | | （如有） | | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | ...

证券代码：002742 证券简称：*ST三圣 公告编号：2025-49号 重庆三圣实业股份有限公司 关于法院许可公司在重整期间继续营业的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年 8 月 8 日，重庆三圣实业股份有限公司（以下简称"公司"或 "三圣股份"）收到重庆市第五中级人民法院（以下简称"重庆五中院"或 "法院"）送达的（2025）渝 05 破申 224 号《民事裁定书》，重庆五中院裁定 受理公司的重整申请。同日，公司收到重庆五中院送达的（2025）渝 05 破 297 号《决定书》，重庆五中院指定北京市金杜（深圳）律师事务所和信永中和会 计师事务所（特殊普通合伙）重庆分所担任公司管理人，管理人负责人为李锴。 具体内容详见公司于 2025 年 8 月 8 日于指定信息披露媒体披露的《关于法院裁 定受理公司重整并指定管理人暨公司股票交易将被叠加实施退市风险警示的公 告》（公告编号：2025-45 号）。 2、截至目前，公司重整工作正有序推进中。如公司顺利实施重整并执行 完毕重整计划，将有利于改善公司资产负债结构及经营状 ...

Financial Performance - The company's operating revenue for the reporting period was ¥486,347,592.22, a decrease of 33.89% compared to ¥735,672,725.36 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥130,978,549.31, representing a decline of 97.02% from -¥66,479,955.50 year-on-year[19]. - The net cash flow from operating activities improved to ¥7,150,445.12, a significant increase of 140.78% compared to -¥17,532,460.82 in the previous year[19]. - The total assets at the end of the reporting period were ¥2,476,505,058.57, down 5.69% from ¥2,626,041,333.84 at the end of the previous year[19]. - The company reported a weighted average return on net assets of 27.24%, an increase of 48.69% compared to -21.45% in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was -¥126,905,323.60, a decrease of 136.51% from -¥53,657,306.43 in the previous year[19]. - The company’s net assets attributable to shareholders decreased to -¥549,825,152.76, a decline of 33.51% from -¥411,810,939.89 at the end of the previous year[19]. - The company reported a net cash increase of ¥-6,966,388.53, which was an improvement of 77.42% compared to ¥-30,856,156.07 from the previous period[35]. - The company reported a significant increase in other payables from CNY 266,471,526.78 to CNY 342,862,589.74, an increase of about 28.6%[145]. - The company reported a gross profit margin of approximately -24% for the current period, compared to -3.3% in the previous period[152]. Business Segments - The construction materials and chemical segment remains the main business, with a focus on ready-mixed concrete and additives, although market demand has sharply declined[26]. - The pharmaceutical manufacturing segment includes intermediates, active pharmaceutical ingredients (APIs), and formulation products, with key intermediates like procaine hydrochloride and chloramphenicol holding leading market positions[27]. - The pharmaceutical segment accounted for 59.77% of total revenue, generating ¥290,705,551.09, despite a 20.68% decline year-over-year[37]. - The construction materials and chemicals segment saw a significant drop in revenue, contributing only 39.94% with ¥194,239,128.52, down 46.02% from the previous year[37]. - The company has diversified into pharmaceutical manufacturing, reducing operational risks associated with macroeconomic cycles, and enhancing profitability through strategic management adjustments[28]. - The company is one of the largest producers of concrete additives in Southwest China, offering a wide range of customized solutions to meet diverse market needs[31]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares for this period[4]. - The company plans to implement a diversification and internationalization strategy to mitigate risks associated with the declining construction materials industry[52]. - The company has formed a dual-driven business model of "building materials + pharmaceutical manufacturing," effectively mitigating raw material market fluctuations and optimizing resource sharing[33]. - The company is strategically located in Chongqing, benefiting from its designation as a national important central city and a key point in the "Belt and Road" initiative, which is expected to drive future growth opportunities[33]. - The company emphasizes technological research and development, establishing a research center for concrete additives and pharmaceuticals to support its production and operational needs[29]. - The company has established a comprehensive drug research and development system, focusing on antibiotics, digestive, respiratory, endocrine, and cardiovascular drugs, with a robust pipeline for antiviral and diabetes medications[30]. Legal and Compliance Issues - The company is facing significant financial pressure and has applied for bankruptcy reorganization, which has been accepted by the court[53]. - The company is actively managing its legal risks and disputes to minimize financial impact[66]. - The company is involved in a second-instance trial for a dispute valued at 89.06 million CNY, with no liability recognized[66]. - The company has reached mediation agreements in several cases, with payments pending from the opposing parties[67]. - The company has not reported any non-compliance issues regarding external guarantees during the reporting period[62]. - The company has no significant related party transactions during the reporting period[72]. Shareholder Information - The total number of shares outstanding is 432,000,000, with 100% being unrestricted shares[131]. - The largest shareholder, Pan Xianwen, holds 17.26% of the shares, totaling 74,554,232 shares, which are currently frozen[132]. - The company has a total of 11,319 shareholders at the end of the reporting period[132]. - The number of unrestricted shares is 431,858,082, representing 99.97% of total shares[130]. - The company does not have any ongoing share repurchase programs or significant changes in shareholding structure reported[131]. Financial Liabilities and Guarantees - The company has a total outstanding principal of RMB 44,200.00 million as of June 30, 2025[98]. - The company has not repaid the principal amount of RMB 772.12 million owed to Agricultural Bank of China as of June 30, 2025[101]. - The total guarantee amount for the company (sum of the three major items) is CNY 298.51 billion, with a total actual guarantee amount of CNY 259.12 billion[87]. - The company has pledged 100% equity of Liaoyuan Baikang Pharmaceutical Co. for a loan of CNY 64 million, which is overdue[125]. - The company has entered a forced execution phase for loans totaling CNY 64 million due to financial difficulties[115]. Future Outlook - The company plans to explore potential mergers and acquisitions to strengthen its market presence[171]. - Future guidance suggests a conservative growth outlook, with expected revenue growth of approximately 5% in the next quarter[167]. - The company has set a revenue guidance of 1.5 billion yuan for the next fiscal year, aiming for a growth rate of approximately 20%[171]. - The company plans to expand its market presence through strategic partnerships and new product launches in the upcoming quarters[171].

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Group 1 - The stock price of *ST San Sheng (002742) closed at 4.8 yuan, down 3.03%, with a turnover rate of 4.16% and a trading volume of 179,700 hands, amounting to 87.37 million yuan [1] - The net outflow of main funds today was 15.92 million yuan, accounting for 18.23% of the transaction amount, with large orders seeing a net outflow of 9.31 million yuan (10.66%) and 6.61 million yuan (7.57%) respectively [1] - The latest financial report shows that the total operating revenue for the first quarter of 2025 was 235 million yuan, a year-on-year decrease of 32.52%, and the net profit attributable to shareholders was 82.38 million yuan, down 132.59% [1] Group 2 - Chongqing San Sheng Industrial Co., Ltd. was established in 2002 and is primarily engaged in the non-metallic mineral products industry, with a registered capital of 432 million yuan and paid-in capital of 72.16 million yuan [1] - The company has made investments in 21 enterprises and participated in 69 bidding projects, holding 53 trademark registrations and 70 patents, along with 114 administrative licenses [2]